Menu
Search
|

Menu

Close
X

TESARO Inc TSRO.OQ (NASDAQ Stock Exchange Global Select Market)

60.00 USD
-1.03 (-1.69%)
As of Feb 16
chart
Previous Close 61.03
Open 60.60
Volume 270,534
3m Avg Volume 304,043
Today’s High 62.71
Today’s Low 60.00
52 Week High 192.94
52 Week Low 55.02
Shares Outstanding (mil) 54.18
Market Capitalization (mil) 6,492.51
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 22 analysts

KEY STATS

Revenue (mm, USD)
FY17
33
FY16
44
FY15
0
EPS (USD)
FY17
-5.364
FY16
-8.092
FY15
-6.363
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
160.34
5.77
Price to Book (MRQ)
vs sector
16.23
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
34.37
16.52
LT Debt to Equity (MRQ)
vs sector
34.37
12.22
Return on Investment (TTM)
vs sector
-125.62
14.43
Return on Equity (TTM)
vs sector
-185.12
16.13

EXECUTIVE LEADERSHIP

David Mott
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Mary Hedley
President, Chief Operating Officer, Director, Since 2014
Salary: $584,462.00
Bonus: --
Leon Moulder
Chief Executive Officer, Director, Since 2010
Salary: $639,385.00
Bonus: --
Timothy Pearson
Chief Financial Officer, Executive Vice President, Principal Accounting Officer, Since 2017
Salary: $402,058.00
Bonus: --
Jeffrey Hanke
Executive Vice President - Research and Development, Chief Scientific Officer, Since 2015
Salary: $411,815.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1000 Winter St Ste 3300
WALTHAM   MA   02451-1230

Phone: +1339.9700900

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

SPONSORED STORIES